Medical technology company Integer Holdings (NYSE: ITGR) will be reporting results this Thursday morning. Here’s what you need to know.

Integer Holdings met analysts’ revenue expectations last quarter, reporting revenues of $467.7 million, up 8.4% year on year. It was a slower quarter for the company, with full-year EBITDA guidance missing analysts’ expectations significantly and full-year revenue guidance slightly missing analysts’ expectations.

Is Integer Holdings a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Integer Holdings’s revenue to grow 2.9% year on year to $462.7 million, slowing from the 11.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.70 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Integer Holdings has missed Wall Street’s revenue estimates four times over the last two years.

Looking at Integer Holdings’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Haemonetics’s revenues decreased 2.7% year on year, beating analysts’ expectations by 2.4%, and Inspire Medical Systems reported revenues up 12.2%, topping estimates by 1.1%. Haemonetics traded down 10% following the results while Inspire Medical Systems was also down 12.5%.

Read our full analysis of Haemonetics’s results here and Inspire Medical Systems’s results here.

The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. Integer Holdings is up 2.9% during the same time and is heading into earnings with an average analyst price target of $85.57 (compared to the current share price of $87.67).

P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.